Cited by 369Liver Disease Diagnosis and TreatmentCholesterol and Lipid MetabolismCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH

Caballero, Francisco, Fernández, Anna, De Lacy, Antonio M., Fernández-Checa, Jose C., Caballería, Juan, García-Ruiz, Carmen·2009·Journal of Hepatology

DOI 10.1016/j.jhep.2008.12.016

Open this paper in CoChat — free account

Abstract

Background/aims Non-alcoholic fatty liver disease (NAFLD) pathogenesis remains unknown. Due to the emerging role of free cholesterol (FC) in NAFLD, our aim was to examine the correlation between FC accumulation in patients with NAFLD and the expression of enzymes that regulate cholesterol homeostasis. Methods Filipin staining, indicative of FC accumulation, and real-time PCR analyses were performed in 31 NAFLD patients and in seven controls. Results All NASH patients (n=14) and 4 out of 17 patients with steatosis exhibited filipin staining compared to controls (0 out of 7 subjects with normal liver histology and BMI). Sterol regulatory element-binding protein-2 (SREBP-2) mRNA levels were 7- and 3-fold higher in NASH and steatosis patients, respectively, compared to controls. Since hydroxymethylglutaryl-CoA (HMG-CoA) reductase is the key enzyme in cholesterol synthesis and transcriptionally controlled by SREBP-2 we measured its mRNA levels, being 3- to 4-fold higher in NAFLD compared to controls, without any difference between NASH and steatosis patients. Fatty acid synthase (FAS) and SREBP-1c expression were not significantly induced in NAFLD, while ATP-binding cassette sub-family G member 1 (ABCG1), a transporter involved in cholesterol egress, and acyl-CoA-cholesterol acyltransferase mRNA levels were modestly increased (1.5- to 2.5-fold, p<0.05), regardless of fibrosis. Interestingly, mRNA levels of steroidogenic acute regulatory protein (StAR), a mitochondrial-cholesterol transporting polypeptide, increased 7- and 15-fold in steatosis and NASH patients, respectively, compared to controls. Conclusions FC increases in NASH and correlates with SREBP-2 induction. Moreover, StAR overexpression in NASH suggests that mitochondrial FC may be a player in disease progression and a novel target for intervention.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2008.12.016

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor
Brown, M. S., & Goldstein, J. L. (1997) · Cell · doi:10.1016/s0092-8674(00)80213-5 · Cited by 3,834
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772
Cellular cholesterol trafficking and compartmentalization
Ikonen, E. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2336 · Cited by 1,506

Flagged first, then by citations

Show all 39 references

1 of the 39 references couldn’t be matched to a known paper.

Sorted by citations

Items 201–300 of 369

Probiotics suppress nonalcoholic steatohepatitis and carcinogenesis progression in hepatocyte-specific PTEN knockout mice
Arai, N., Miura, K., Aizawa, K., Sekiya, M., Nagayama, M., Sakamoto, H., Maeda, H., Morimoto, N., Iwamoto, S., & Yamamoto, H. (2022) · Scientific Reports · doi:10.1038/s41598-022-20296-3 · Cited by 25
Metabolic injury of hepatocytes promotes progression of NAFLD and AALD
Carvalho-Gontijo, R., Han, C., Zhang, L., Zhang, V., Hosseini, M., Mekeel, K., Schnabl, B., Loomba, R., Karin, M., Brenner, D. A., et al. (2022) · Seminars in Liver Disease · doi:10.1055/s-0042-1755316 · Cited by 23
Complementary Gene Regulation by NRF1 and NRF2 Protect Against Hepatic Cholesterol Overload
Akl, M. G., Li, L., Baccetto, R., Phanse, S., Zhang, Q., Trites, M. J., McDonald, S., Aoki, H., Babu, M., & Widenmaier, S. B. (2022) · Cell Reports · doi:10.1016/j.celrep.2023.112399 · Cited by 29
Alliin attenuates 1, 3-dichloro-2-propanol-induced lipogenesis in HepG2 cells through activation of the AMP-activated protein kinase-dependent pathway
Lu, J., Cheng, B., Meng, Z., Fang, B., Li, T., Sun, M.-C., Liu, M., & Guan, S. (2018) · Life Sciences · doi:10.1016/j.lfs.2017.12.040 · Cited by 24
Recovery from liver disease in a Niemann-Pick type C mouse model
Sayre, N. L., Rimkunas, V. M., Graham, M. J., Crooke, R. M., & Liscum, L. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m007211 · Cited by 23
Role of FDFT 1 polymorphism for fibrosis progression in patients with chronic hepatitis C
Stättermayer, A. F., Rutter, K., Beinhardt, S., Wrba, F., Scherzer, T. M., Straßer, M., Hofer, H., Steindl‐Munda, P., Trauner, M. A., & Ferenci, P. (2013) · Liver International · doi:10.1111/liv.12269 · Cited by 23
Dual inhibition of ACLY and ACSS2 by EVT0185 reduces steatosis, hepatic stellate cell activation, and fibrosis in mouse models of MASH
Steinberg, G. R., Gautam, J., Lally, J., Fayyazi, R., Grasset, E., Bhattacharya, D., Fidelito, G., Ahmadi, E., Townsend, L. K., Batchuluun, B., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2025.11.015 · Cited by 23
Risk Factors of Non-alcoholic Fatty Liver Disease in the Iranian Adult Population: A Systematic Review and Meta-analysis
Amini‐Salehi, E., Hassanipour, S., Joukar, F., Daryagasht, A. A., Khosousi, M., Aleali, M. S., Ansar, M. M., Heidarzad, F., Abdzadeh, E., Vakilpour, A., et al. (2023) · Hepatitis Monthly · doi:10.5812/hepatmon-131523 · Cited by 22
Olive Oil Attenuates the Cholesterol-induced Development of Nonalcoholic Steatohepatitis Despite Increased Insulin Resistance in a Rodent Model
Buettner, R., Ascher, M., Gäbele, E., Hellerbrand, C., Kob, R., Bertsch, T., & Bollheimer, L. C. (2013) · Hormone and Metabolic Research · doi:10.1055/s-0033-1353209 · Cited by 22
Synthesis of heterocyclic ring-fused analogs of HMG499 as novel degraders of HMG-CoA reductase that lower cholesterol
Li, X.-Z., Jiang, S., Li, G., Jiang, Q.-R., Li, J., Li, C., Han, Y.-Q., Song, B., Ma, X., Qi, W., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114323 · Cited by 21
Gypenoside L inhibits hepatocellular carcinoma by targeting the SREBP2-HMGCS1 axis and enhancing immune response
Xiao, M.-Y., Pei, W.-J., Li, S., Li, F.-F., Xie, P., Luo, H.-T., Hyun Yoo, H., & Piao, X.-L. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107539 · Cited by 26
Is hepatic lipogenesis fundamental for NAFLD/NASH? A focus on the nuclear receptor coactivator PGC-1β
Ducheix, S., Vegliante, M. C., Villani, G., Napoli, N., Sabbà, C., & Moschetta, A. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2331-x · Cited by 23
Preventive effect of trans-chalcone on non-alcoholic steatohepatitis: Improvement of hepatic lipid metabolism
Karimi‐Sales, E., Kalan, A. E., & Alipour, M. R. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.196 · Cited by 24
Damaging mutations in liver X receptor-α are hepatotoxic and implicate cholesterol sensing in liver health
Lockhart, S. M., Mušo, M., Zvetkova, I., Lam, B., Ferrari, A., Schoenmakers, E., Duckett, K., Leslie, J., Collins, A., Romartínez-Alonso, B., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01126-4 · Cited by 23
Coffee modulates insulin-hepatocyte nuclear factor-4α-Cyp7b1 pathway and reduces oxysterol-driven liver toxicity in a nonalcoholic fatty liver disease mouse model
Kakiyama, G., Minowa, K., Rodríguez‐Agudo, D., Martin, R., Takei, H., Mitamura, K., Ikegawa, S., Suzuki, M., Nittono, H., Fuchs, M. A., et al. (2022) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00179.2022 · Cited by 20
Ethanol extract of Zhongtian hawthorn lowers serum cholesterol in mice by inhibiting transcription of 3-hydroxy-3-methylglutaryl-CoA reductase via nuclear factor-kappa B signal pathway
Hu, H., Luo, X., Dong, Q., Mu, A., Shi, G.-L., Wang, Q., Chen, X.-Y., Zhou, H., Zhang, T., & Pan, L.-W. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370215627032 · Cited by 20
A mutation in LXRα uncovers a role for cholesterol sensing in limiting metabolic dysfunction-associated steatohepatitis
Clark, A. T., Russo-Savage, L., Ashton, L. A., Haghshenas, N., Amselle, N. A., & Schulman, I. G. (2025) · Nature Communications · doi:10.1038/s41467-025-56565-8 · Cited by 19
Inhibition of lysosomal LAMTOR1 increases autophagy by suppressing the MTORC1 pathway to ameliorate lipid accumulations in MAFLD
Jang, Y., Ko, M., Lee, J. Y., Kim, J. Y., Lee, E., & Kwon, H. J. (2025) · Autophagy · doi:10.1080/15548627.2025.2519054 · Cited by 19
Nonalcoholic Fatty Liver Disease.
Ding, L.-L., Oligschlaeger, Y., Shiri-Sverdlov, R., & Houben, T. (2020) · Handbook of Experimental Pharmacology · doi:10.1007/164_2020_352 · Cited by 4
Integrating Network Pharmacology and RT-qPCR Analysis to Investigate the Mechanisms Underlying ZeXie Decoction-Mediated Treatment of Non-alcoholic Fatty Liver Disease
Wu, J., Zhang, F., Ruan, H., Chang, X., Wang, J., Li, Z., Jin, W., & Shi, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.722016 · Cited by 19
Endoplasmic reticulum stress at the forefront of fatty liver diseases and cancer
Karin, M., & Kim, J. Y. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100096 · Cited by 20
Elucidating Potential Profibrotic Mechanisms of Emerging Biomarkers for Early Prognosis of Hepatic Fibrosis
Zehra, M., Curry, J. C., Pillai, S. S., Lakhani, H. V., Edwards, C. E., & Sodhi, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134737 · Cited by 17
Transcription factor binding site enrichment analysis predicts drivers of altered gene expression in nonalcoholic steatohepatitis
Lake, A. D., Chaput, A., Novák, P., Cherrington, N. J., & Smith, C. L. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.006 · Cited by 19
Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice
Lin, C., Yu, B., Chen, L., Zhang, Z., Ye, W., Zhong, H., Bai, W., Yang, Y., & Nie, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.880508 · Cited by 17
Pathogenesis of Nonalcoholic Fatty Liver Disease
Machado, M. V., & Diehl, A. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-37591-7.00025-2 · Cited by 17
Eicosapentaenoic Acid‐Enriched Phosphatidylcholine Attenuated Hepatic Steatosis Through Regulation of Cholesterol Metabolism in Rats with Nonalcoholic Fatty Liver Disease
Liu, Y., Shi, D., Tian, Y., Liu, Y., Zhan, Q., Xu, J., Wang, J., & Xue, C. (2016) · Lipids · doi:10.1007/s11745-016-4222-1 · Cited by 17
MRI of atherosclerosis and fatty liver disease in cholesterol fed rabbits
Taylor, E. N., Huang, N., Bodde, J., Ellison, A., Killiany, R., Bachschmid, M. M., & Hamilton, J. A. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1587-3 · Cited by 17
Polymorphism in the Farnesyl Diphosphate Farnesyl Transferase 1 Gene and Nonalcoholic Fatty Liver Disease Severity
Ballestri, S., Day, C. P., & Daly, A. K. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.01.060 · Cited by 17
Atorvastatin Attenuates Diet-Induced Non-Alcoholic Steatohepatitis in APOE*3-Leiden Mice by Reducing Hepatic Inflammation
Inia, J. A., Stokman, G., Pieterman, E. J., Morrison, M. C., Menke, A. L., Verschuren, L., Caspers, M. P. M., Giera, M. A., Jukema, J. W., van den Hoek, A. M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097818 · Cited by 21
Unlocking Cholesterol Metabolism in Metabolic-Associated Steatotic Liver Disease: Molecular Targets and Natural Product Interventions
Li, X., & Li, M. (2024) · Pharmaceuticals · doi:10.3390/ph17081073 · Cited by 17
Changes induced by non-alcoholic fatty liver disease in liver sinusoidal endothelial cells and hepatocytes: spectroscopic imaging of single live cells at the subcellular level
Kochan, K., Kuś, E., Szafraniec, E., Wislocka, A., Chłopicki, S., & Barańśka, M. (2017) · The Analyst · doi:10.1039/c7an00865a · Cited by 16
Artemisia iwayomogi plus Curcuma longa Synergistically Ameliorates Nonalcoholic Steatohepatitis in HepG2 Cells
Kim, H.-G., Lee, S.-B., Lee, J., Kim, W., Choi, S., & Son, C. (2017) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2017/4390636 · Cited by 16
A targeted multi-omics approach reveals paraoxonase-1 as a determinant of obesity-associated fatty liver disease
Diels, S., Cuypers, B., Tvarijonaviciute, A., Derudas, B., Dijck, E. V., Verrijken, A., Gaal, L. F. V., Laukens, K., Lefèbvre, P., Cerón, J. M. C., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01142-1 · Cited by 16
Bile acids in liver and gastrointestinal cancer
Monte, M. J., Fàbrega, L., Romero, M. R., Temprano, Á. G., Kaplowitz, N., García‐Ruiz, C., Marı́n, J. J. G., & Fernández-Checa, J. C. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.09.002 · Cited by 16
Self-citation
Impact of mitochondrial lipid alterations on liver disease mechanisms and progression
Fàbrega, L., Fernández-Checa, J. C., de la Rosa, L. C., & García‐Ruiz, C. (2024) · Exploration of Digestive Diseases · doi:10.37349/edd.2024.00057 · Cited by 16
Self-citation
Circulating indian hedgehog is a marker of the hepatocyte-TAZ pathway in experimental NASH and is elevated in humans with NASH
Moore, M. P., Wang, X., Shi, H., Meroni, M., Cherubini, A., Ronzoni, L., Parks, E. J., Ibdah, J. A., Rector, R. S., Valenti, L. V. C., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100716 · Cited by 16
Non‐Alcoholic Fatty Liver Disease and Nutrition
Caldwell, S. H., & Argo, C. K. (2011) · Wiley eBooks · doi:10.1002/9781444341294.ch28 · Cited by 16
Inhibition of microRNA-33b in humanized mice ameliorates nonalcoholic steatohepatitis
Miyagawa, S., Horie, T., Nishino, T., Koyama, S., Watanabe, T., Baba, O., Yamasaki, T., Sowa, N., Otani, C., Matsushita, K., et al. (2023) · Life Science Alliance · doi:10.26508/lsa.202301902 · Cited by 14
Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models
Basha, A., May, S. C., Anderson, R. M., Samala, N. R., & Mirmira, R. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129996 · Cited by 14
Genetic and metabolic aspects of non-alcoholic fatty liver disease (NAFLD) pathogenicity
Samarasinghe, S. M., Hewage, A. S., Siriwardana, R. C., Tennekoon, K. H., Niriella, M. A., & Silva, S. D. (2023) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-023-00433-x · Cited by 15
Liver-specific microRNA-185 knockout promotes cholesterol dysregulation in mice
Chen, C., Matye, D. J., Wang, Y., & Li, T. (2020) · Liver Research · doi:10.1016/j.livres.2020.09.001 · Cited by 14
Oxidative Stress in Nonalcoholic Fatty Liver Disease
Marí, M., Morales, A., Colell, A., García‐Ruiz, C., & Fernández-Checa, J. C. (2015) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-3-319-15539-5_12 · Cited by 14
Self-citation
Should We Lower Lipids in Nonalcoholic Fatty Liver Disease?
Farrell, G. C. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.07.041 · Cited by 14
Evaluation of sucrose-enriched diet consumption in the development of risk factors associated to type 2 diabetes, atherosclerosis and non-alcoholic fatty liver disease in a murine model
Guerrero, C. G. P., Acosta-Cota, S. D. J., Castro‐Sanchez, F. H., Vergara-Jiménez, M. D. J., Burgueño, E. R. R., Sarmiento‐Sánchez, J. I., Picos‐Corrales, L. A., & Osuna‐Martínez, U. (2019) · International Journal of Environmental Health Research · doi:10.1080/09603123.2019.1680817 · Cited by 14
Assessment of Genetic Aspects of Non-alcoholic Fatty Liver and Premature Cardiovascular Events
Saki, S., Saki, N., Poustchi, H., & Malekzadeh, R. (2020) · Middle East Journal of Digestive Diseases · doi:10.34172/mejdd.2020.166 · Cited by 14
Sterol O-acyltransferase (SOAT/ACAT) activity is required to form cholesterol crystals in hepatocyte lipid droplets
Bairos, J. A., Njoku, U. C., Zafar, M., Akl, M. G., Li, L., Parlakgül, G., Arruda, A. P., & Widenmaier, S. B. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2024.159512 · Cited by 13
Disruption of cholesterol homeostasis triggers NLRP3-cGAS-STING axis-dependent hepatic fibrosis and honokiol intervention effects
Wang, Z., Liu, J., Mou, Y., Zhou, X., Liao, W., Li, Y., Liu, Y., & Tang, J. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156904 · Cited by 14
CYNARA SCOLYMUS FOR RELIEVING ON NONALCOHOLIC STEATOHEPATITIS INDUCED IN RATS
Mohamed, S. H., Ahmed, H. H., Farrag, A. R. H., Abdel‐Azim, N. S., & Shahat, A. A. (2013) · Cited by 12
Exercise‐Induced Changes in Caveolin‐1, Depletion of Mitochondrial Cholesterol, and the Inhibition of Mitochondrial Swelling in Rat Skeletal Muscle but Not in the Liver
Flis, D. J., Olek, R. A., Kaczor, J. J., Rodziewicz-Flis, E. A., Hałoń, M., Antosiewicz, J., Woźniak, M., Gabbianelli, R., & Ziółkowski, W. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/3620929 · Cited by 12
Zoledronic acid prevents the hepatic changes associated with high fat diet in rats; the potential role of mevalonic acid pathway in nonalcoholic steatohepatitis
Mohamed, R. H., Tarek, M., Hamam, G. G., & Ezzat, S. F. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172469 · Cited by 12
Emerging therapeutic targets for NASH: key innovations at the preclinical level
Horn, P., & Newsome, P. N. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1728742 · Cited by 12
Targeted inhibition of PPAR α ameliorates CLA ‐induced hypercholesterolemia via hepatic cholesterol biosynthesis reprogramming
Liu, H., Hu, P., Li, Y., Sun, M., Qu, H., Zong, Q., Gu, H., Chen, X., Bao, W., & Cai, D. (2022) · Liver International · doi:10.1111/liv.15199 · Cited by 12
Liver fat content is associated with an increase in cholesterol synthesis independent of statin therapy use in patients with type 2 diabetes
Brindisi, M., Guiu, B., Duvillard, L., Athias, A., Rollot, F., Bouillet, B., Beacco, M., Hillon, P., Cercueil, J., Vergès, B. L., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.08.016 · Cited by 12
Overactivation of intestinal sterol response element-binding protein 2 promotes diet-induced nonalcoholic steatohepatitis
Malhotra, P., Aloman, C., Ankireddy, A., Khadra, H., Ooka, K., Gill, R. K., Saksena, S., Dudeja, P. K., & Alrefai, W. A. (2017) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00174.2017 · Cited by 12
Relationship of SREBP-2 rs2228314 G>C Polymorphism with Nonalcoholic Fatty Liver Disease in a Han Chinese Population
Wang, Y., Tong, J., Chang, B., Wang, B., Zhang, D., & Wang, B. (2014) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2014.0116 · Cited by 12
Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin
Meroni, M., Longo, M., & Dongiovanni, P. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1411706 · Cited by 12
Hepatic Transporters Alternations Associated with Non-alcoholic Fatty Liver Disease (NAFLD): A Systematic Review
Omidkhoda, N., Zare, S., Mahdiani, S., Samadi, S., Akhlaghi, F., & Mohammadpour, A. H. (2022) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-022-00802-8 · Cited by 11
The hepatic effects of GDF11 on health and disease
Gerardo‐Ramírez, M., German-Ramirez, N., Escobedo‐Calvario, A., Chávez-Rodríguez, L., Bucio, L., Souza-Arroyo, V., Miranda-Labra, R. U., Gutiérrez‐Ruíz, M. C., & Gómez-Quiroz, L. E. (2022) · Biochimie · doi:10.1016/j.biochi.2022.12.017 · Cited by 12
Hepatic Macrophages as Targets for the MSC-Based Cell Therapy in Non-Alcoholic Steatohepatitis
Kholodenko, I. V., & Yarygin, K. N. (2023) · Biomedicines · doi:10.3390/biomedicines11113056 · Cited by 14
S-adenosylmethionine deficit disrupts very low-density lipoprotein metabolism promoting liver lipid accumulation in mice
Luque-Urbano, M. R., Fernández‐Ramos, D., Lopitz‐Otsoa, F., de Juan, V. G., Bizkarguenaga, M., Castro-Espadas, L., Hermoso-Martínez, U., Barbier‐Torres, L., Lu, S. C.-L., Millet, Ó., et al. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100794 · Cited by 11
Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms
Lequoy, M., Gigante, E., Couty, J., & Desbois‐Mouthon, C. (2020) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2019-0044 · Cited by 12
Protein Arginine Methyltransferase 4 Regulates Adipose Tissue Lipolysis in Type 1 Diabetic Mice
Li, Y., Peng, M., Zeng, T., Zheng, J., Liao, Y., Zhang, H., Yang, S., & Chen, L. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s235869 · Cited by 10
Impact of high fat diet on the sterol regulatory element-binding protein 2 cholesterol pathway in the testicle
Funes, A. K., Simón, L., Colombo, R., Avena, M. V., Monclus, M. A., Crescitelli, J., Cabrillana, M. E., Conte, M. I., Cayado-Gutiérrez, N., Boarelli, P. V., et al. (2021) · Molecular Human Reproduction · doi:10.1093/molehr/gaab023 · Cited by 10
Genetics of non-alcoholic fatty liver disease and associated metabolic disorders
Hernáez, R. (2011) · Avances en Diabetología · doi:10.1016/j.avdiab.2011.11.004 · Cited by 10
ABO blood group and risk of newly diagnosed nonalcoholic fatty liver disease: A case-control study in Han Chinese population
Zhong, G., Liu, S., Wu, Y., Xia, M., Zhu, J., Hao, F., & Wan, L. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225792 · Cited by 12
Niemann-Pick type C2 protein supplementation in experimental non-alcoholic fatty liver disease
Christensen, C. U., Glavind, E., Thomsen, K. L., Kim, Y. O., Heebøll, S., Schuppan, D., Hamilton-Dutoit, S. J., Heegaard, C. W., & Grønbæk, H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192728 · Cited by 9
Lack of Augmenter of Liver Regeneration Disrupts Cholesterol Homeostasis of Liver in Mice by Inhibiting the AMPK Pathway
Wang, X., Dong, L., Gai, Q., Ai, W., Wu, Y. S., Xiao, W., Zhang, J., & An, W. (2020) · Hepatology Communications · doi:10.1002/hep4.1532 · Cited by 8
Effects of monobutyl phthalate on steroidogenesis through steroidogenic acute regulatory protein regulated by transcription factors in mouse Leydig tumor cells
Hu, Y., Dong, C., Chen, M., Chen, Y., Gu, A., Xia, Y., Sun, H., Li, Z., & Wang, Y. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0279-6 · Cited by 9
Roles of Yes-associated protein and transcriptional coactivator with PDZ-binding motif in non-neoplastic liver diseases
Chen, D., Zhang, H., Zhang, X., Sun, X., Qin, Q., Hou, Y., Jia, M., & Chen, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113166 · Cited by 8
Cholesterol overload in macrophages drives metabolic dysfunction-associated steatohepatitis via inhibiting 7-dehydrocholesterol reductase in mice
Li, X., Wang, K., Sun, Y., Wang, Y., Wu, J., Dang, Y., Li, M., & Zhou, W. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05905-1 · Cited by 8
Melanocortin 1 receptor regulates cholesterol and bile acid metabolism in the liver
Thapa, K., Kadiri, J. J., Saukkonen, K., Pennanen, I., Ghimire, B. R., Cai, M., Savontaus, E., & Rinne, P. (2023) · eLife · doi:10.7554/elife.84782 · Cited by 9
[Cholesterol overload in hepatocytes affects nicotinamide adenine dinucleotide phosphate oxidase (NADPH) activity abrogating hepatocyte growth factor (HGF) induced cellular protection].
López-Reyes, A. G., Martínez‐Flores, K., Clavijo‐Cornejo, D., Nuño‐Lámbarri, N., Domínguez, M. P., Souza, V., Bucio, L., Panduro, A., Miranda, R. U., Gómez-Quiroz, L. E., et al. (2015) · PubMed · Cited by 8
Role of cholesterol homeostasis in MASH-driven hepatocellular carcinoma: not just a neutral fat
Ribas, V. (2024) · Exploration of Digestive Diseases · doi:10.37349/edd.2024.00048 · Cited by 8
Cholesterol metabolism and expression of its relevant genes in cultured steatotic hepatocytes
Xiao Hong, W. A. N. G., Tian, Y., Guo, Z. J., Fan, Z., Qiu, D., & Min De, Z. E. N. G. (2009) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2009.00401.x · Cited by 7
Redox Regulation by HGF/c-Met in Liver Disease
Gómez-Quiroz, L. E., Gutiérrez‐Ruíz, M. C., Marquardt, J. U., Factor, V., & Thorgeirsson, S. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804274-8.00029-1 · Cited by 7
Nonalcoholic Fatty Liver Disease
Argo, C. K., Henry, Z. H., & Caldwell, S. H. (2017) · Wiley eBooks · doi:10.1002/9781119251316.ch32 · Cited by 7
Genetic and metabolic characterization of individual differences in liver fat accumulation in Atlantic salmon
Horn, S. S., Sonesson, A. K., Krasnov, A., Aslam, M. L., Hillestad, B., & Ruyter, B. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1512769 · Cited by 6
Sterol Regulatory Element-Binding Proteins and Metabolic Diseases: Mechanisms, Implications, and Therapeutic Strategies
Zhang, X., Zhang, K., Wang, Y., Fan, Q., Kan, C., Ma, Y., Sheng, S., Hou, N., & Sun, X. (2025) · Metabolic Syndrome and Related Disorders · doi:10.1177/15578518251407655 · Cited by 6
Impact of Seipin in cholesterol mediated lipid droplet maturation; status of endoplasmic reticulum stress and lipophagy
Demirel-Yalçıner, T., Cetinkaya, B., Sözen, E., & Özer, N. K. (2024) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2024.111933 · Cited by 6
Association Between Four ABCA1 gene Polymorphisms and Risk of Non-Alcoholic Fatty Liver Disease in a Chinese Han Population
Wang, C., Liu, S., Lu, L., Liao, S., Yue, H., Dong, Q., Xin, Y., & Xuan, S. (2018) · Hepatitis Monthly · doi:10.5812/hepatmon.66149 · Cited by 6
Nonalcoholic Fatty Liver Disease
Caldwell, S. H., Argo, C. K., & Al‐Osaimi, A. M. S. (2011) · Wiley eBooks · doi:10.1002/9781119950509.ch32 · Cited by 6
Effects of lacidophilin in a mouse model of low-grade colitis and nonalcoholic fatty liver disease
Zhan, Y., Cheng, X.-Y., Li, T., Li, Y.-M., Sun, D., Guo, F.-H., Sun, Y., Li, Q., Zhang, H., & Liu, W.-J. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.104469 · Cited by 5
Hyperactivation of SREBP induces pannexin-1-dependent lytic cell death
Xiong, Y., Luo, J., Hong, Z.-Y., Zhu, W.-Z., Hu, A., & Song, B.-L. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100579 · Cited by 5
Immunometabolic factors contributing to obesity-linked hepatocellular carcinoma
Akl, M. G., & Widenmaier, S. B. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1089124 · Cited by 6
Cholesterol Regulation by Leptin in Alcoholic Liver Disease
Vairappan, B. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800773-0.00015-x · Cited by 5
Exploration of the Key Genes Involved in Non-alcoholic Fatty Liver Disease and Possible MicroRNA Therapeutic Targets
Mahmoudi, A. A., Jalili, A., Butler, A. E., Aghaee‐Bakhtiari, S. H., Jamialahmadi, T., & Sahebkar, A. (2024) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2024.101365 · Cited by 5
Molecular Mechanisms of Lipotoxicity in Nonalcoholic Fatty Liver Disease
Cazanave, S. C., & Sanyal, A. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-25065-6_5 · Cited by 5
Lipid Modifiers and NASH: Statins, Ezetimibe, Fibrates, and Other Agents
Musso, G., Molinaro, F., Paschetta, E., Gambino, R., & Cassader, M. (2013) · doi:10.1002/9781118556153.ch26 · Cited by 5
Increased Steroidogenic Acute Regulatory Protein Contributes to Cholesterol-induced β-Cell Dysfunction
Akter, R., Hogan, M. F., Esser, N., Barrow, B. M., Castillo, J., Boyko, E. J., Templin, A. T., Hull, R. L., Zraika, S., & Kahn, S. E. (2025) · Endocrinology · doi:10.1210/endocr/bqaf027 · Cited by 4
Gut ribotoxic stress responses facilitate dyslipidemia via metabolic reprogramming: an environmental health prediction
Kim, J., Jeong, H., Ray, N., Kim, K., & Moon, Y. (2024) · Theranostics · doi:10.7150/thno.88586 · Cited by 5
Ablation of histone methyltransferase Suv39h2 in hepatocytes attenuates NASH in mice
Wu, S., Ren, W., Hong, J., Yang, Y., & Lu, Y. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122524 · Cited by 4
Modeling Human Liver Cancer Heterogeneity: Virally Induced Transgenic Models and Mouse Genetic Models of Chronic Liver Inflammation
Ringelhan, M., Reisinger, F., Yuan, D., Weber, A., & Heikenwälder, M. F. (2014) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph1431s67 · Cited by 4
Transcriptome Sequencing Reveals Autophagy Networks in Rat Livers During the Development of NAFLD and Identifies Autophagy Hub Genes
Chen, Y. Q., Zhao, X., Luo, X. M., Zeng, X., Qin, L., Tan, P., He, Q., & Xie, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24076437 · Cited by 4
Factores de riesgo asociados a hígado graso de origen no alcohólico en una población del Caribe Colombiano
Lambis-Anaya, L., Solana-Tinoco, J. B., Gastelbondo, B., Romero, D., Garrido, D., Puello-Ramos, W., García, M., & Suárez, A. (2017) · Revista Colombiana de Gastroenterología · doi:10.22516/25007440.77 · Cited by 4
Emerging Concepts on the Pathogenesis of Non‐Alcoholic Steatohepatitis (NASH)
Leclercq, I. A. (2013) · Wiley eBooks · doi:10.1002/9781118556153.ch5 · Cited by 5
Multifaceted Human Antigen R (HuR): A Key Player in Liver Metabolism and MASLD
Eppler, N., Jones, E., Ahamed, F., & Zhang, Y. (2025) · Livers · doi:10.3390/livers5030033 · Cited by 3
Interleukin-1 Receptor Antagonist as a Potential Mediator Linking Psoriasis and Non-Alcoholic Fatty Liver Disease: Insights From Mendelian Randomization and Experimental Evidence
Shuai, C., Cheung, S., Zhang, L., Cao, H., Yuan, Y., Ge, Q., Wang, Y., Li, X., Zheng, J., & Xue, F. (2025) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s536186 · Cited by 3
Mitochondria and Alcohol
Torres, S., Segalés, P., de la Rosa, L. C., García‐Ruiz, C., & Fernández-Checa, J. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-32483-3_56 · Cited by 3
Self-citation
Cheong-sang-gyeon-tong-tang improves hepatic steatosis by regulating cholesterol metabolism
Kang, Y., Kim, K.-Y., Kim, T. I., Kim, H.-H., Kim, H.-H., & Kim, K. (2024) · Molecular & Cellular Toxicology · doi:10.1007/s13273-024-00426-w · Cited by 3
Longitudinal evaluation of liver stiffness reveals hepatic cholesterol as the determinant of fibrosis progression in mice
Lee, N. Y., & Koo, J. H. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123201 · Cited by 3

Authors: Caballero, F., Fernández, A., De Lacy, A. M., Fernández-Checa, J. C., Caballería, J., & García-Ruiz, C.
Affiliations: Consejo Superior de Investigaciones Científicas (ES)
ORCID: Caballería, Juan
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2009-04
Volume: 50
Issue: 4
Pages: 789-796
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2008.12.016
OpenAlex: W2010101404
Cited by: 368
References: 39
Citations by year: 2026: 9 · 2025: 21 · 2024: 25 · 2023: 26 · 2022: 18 · 2021: 24 · 2020: 28 · 2019: 18 · 2018: 27 · 2017: 24 · 2016: 30 · 2015: 20 · 2014: 21 · 2013: 22 · 2012: 15
FWCI: 12.37
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
Funders: National Institute on Alcohol Abuse and Alcoholism (P50-AA11999, P50AA011999)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, free cholesterol, SREBP2, steroidogenic acute regulatory protein, cholesterol homeostasis, HMG-CoA reductase, ABCG1, acyl-CoA:cholesterol acyltransferase, fatty acid synthase, SREBP-1c, mitochondrial cholesterol transport, steatosis, fibrosis
MeSH terms: ATP Binding Cassette Transporter, Subfamily G, Member 1, Steroidogenic Acute Regulatory Protein, Adult, Animals, Cholesterol, Fatty Liver, Female, Filipin, Humans, Hydroxymethylglutaryl CoA Reductases, Male, Middle Aged, Obesity, Morbid, Phosphoproteins, RNA, Messenger, DNA Primers, Mice, Knockout, ATP-Binding Cassette Transporters, Reverse Transcriptase Polymerase Chain Reaction, Diabetes Complications, Mice, Sterol Regulatory Element Binding Protein 1, Sterol Regulatory Element Binding Protein 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks